This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kondo, N. Articles by Yamashita, H. Search for Related Content PubMed PubMed Citation Articles by Kondo, N. Articles by Yamashita, H.

miR-206 Expression Is Down-regulated in Estrogen Receptor –Positive Human Breast Cancer

Oncology, Immunology, and Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan

Requests for reprints: Hiroko Yamashita, Oncology, Immunology and Surgery, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan. Phone: 1-81-52-853-8231; Fax: 1-81-52-853-6440; E-mail: hirokoy{at}med.nagoya-cu.ac.jp.

Key Words: breast cancer • estrogen receptor • microRNA • miR-206

Expression levels of estrogen receptor (ER) govern estrogen-dependent growth, response to endocrine therapy, and prognosis in ER-positive breast cancer. Multiple mechanisms involved in altering ER gene expression in breast cancer have been identified, including ER gene amplification as well as transcriptional silencing by DNA methylation of CpG islands within the ER promoter and mutations within the open reading frame of ER. However, expression levels of ER in breast cancer tissues differ widely among patients, and frequently change during disease progression and in response to systemic therapies. Recent evidence has shown that microRNA mutations or misexpression correlate with various human cancers, and miR-206 is reported to decrease endogenous ER mRNA and protein levels in human MCF-7 breast cancer cells via two specific target sites within the 3'-untranslated region of the human ER transcript. In this study, we show for the first time that miR-206 expression is markedly decreased in ER-positive human breast cancer tissues assayed by quantitative reverse transcription-PCR analysis. Moreover, we observe that miR-206 expression is inversely correlated with ER but not ERβ mRNA expression in breast cancer tissues. Transfection experiments revealed that introduction of miR-206 into estrogen-dependent MCF-7 breast cancer cells inhibits cell growth in a dose- and time-dependent manner. Our results suggest that miR-206 could be a novel candidate for endocrine therapy that targets only ER in breast cancer. [Cancer Res 2008;68(13):5004–8]

This article has been cited by other articles:

				D. P. Pandey and D. Picard miR-22 Inhibits Estrogen Signaling by Directly Targeting the Estrogen Receptor {alpha} mRNA Mol. Cell. Biol., July 1, 2009; 29(13): 3783 - 3790. [Abstract] [Full Text] [PDF]

				X. LIU, J. YU, L. JIANG, A. WANG, F. SHI, H. YE, and X. ZHOU MicroRNA-222 Regulates Cell Invasion by Targeting Matrix Metalloproteinase 1 (MMP1) and Manganese Superoxide Dismutase 2 (SOD2) in Tongue Squamous Cell Carcinoma Cell Lines Cancer Genomics Proteomics, May 1, 2009; 6(3): 131 - 139. [Abstract] [Full Text] [PDF]

				S M Khoshnaw, A R Green, D G Powe, and I O Ellis MicroRNA involvement in the pathogenesis and management of breast cancer J. Clin. Pathol., May 1, 2009; 62(5): 422 - 428. [Abstract] [Full Text] [PDF]

				C. L. Bartels and G. J. Tsongalis MicroRNAs: Novel Biomarkers for Human Cancer Clin. Chem., April 1, 2009; 55(4): 623 - 631. [Abstract] [Full Text] [PDF]